| Hazard Information | Back Directory | [Uses]
COG 133 TFA is a fragment of Apolipoprotein E (APOE) peptide. COG 133 TFA competes with the ApoE holoprotein for binding the LDL receptor, with potent anti-inflammatory and neuroprotective effects. COG 133 TFA is also a nAChR antagonist with an IC50 of 445 nM[1][2]. | [in vivo]
COG 133 (1 mg/kg; intratracheal administration; every other day; for 4 weeks) treatment impairs the resolution of pulmonary fibrosis in mice[3]. | Animal Model: | Male C57BL/6 mice (6-week-old) instilled with Bleomycin[3] | | Dosage: | 1 mg/kg
| | Administration: | Intratracheal administration; every other day; for 4 weeks | | Result: | Did blunt the resolution of lung fibrosis. |
| [References]
[1] Orleancio Gomes R Azevedo, et al. Apolipoprotein E COG 133 mimetic peptide improves 5-fluorouracil-induced intestinal mucositis. BMC Gastroenterol. 2012 Jul 13;12:35. DOI:10.1186/1471-230X-12-35
[2] Elaine A Gay, et al. Apolipoprotein E-derived peptides block alpha7 neuronal nicotinic acetylcholine receptors expressed in xenopus oocytes. J Pharmacol Exp Ther. 2006 Feb;316(2):835-42. DOI:10.1124/jpet.105.095505
[3] Huachun Cui, et al. Monocyte-derived alveolar macrophage apolipoprotein E participates in pulmonary fibrosis resolution. JCI Insight. 2020 Mar 12;5(5):e134539. DOI:10.1172/jci.insight.134539 |
|
|